Table 1 Baseline comparison of patient characteristics by group, Stop-Stroke in AF study 2010–2012
Variable | Academic Detailing+ Expert Decisional Support n (%) N = 298 | Academic Detailing n (%) N = 292 | Total n (%) N = 590 |
|---|---|---|---|
Sex | |||
 Male | 152 (51.0) | 155 (53.1) | 307 (52.0) |
 Female | 146 (49.0) | 137 (46.9) | 283 (48.0) |
Age Group | |||
  < 65 | 27 (9.1) | 30 (10.3) | 57 (9.7) |
 65–74 | 94 (31.5) | 89 (30.5) | 183 (31.0) |
 75–84 | 117 (39.3) | 114 (39.0) | 231 (39.2) |
 85+ | 60 (20.1) | 59 (20.2) | 119 (20.2) |
 Mean (SD) | 76.5 (9.5) | 76.5 (9.2) | 76.5 (9.4) |
 Median (IQR)s | 77.5 (70–84) | 77.0 (70–83) | 77 (70–84) |
CHADS2score | |||
 0 | 22 (7.4) | 29 (9.9) | 51 (8.6) |
 1 | 57 (19.1) | 71 (24.3) | 128 (21.7) |
 2+ | 212 (71.1) | 189 (64.7) | 401 (68.0) |
 N/A (Cases with valvular AF) | 7 (2.3) | 3 (1.0) | 10 (1.7) |
 Mean (SD) | 2.4 (1.4) | 2.2 (1.4) | 2.3 (1.4) |
 Median (IQR) | 2 (1–3) | 2 (1–3) | 2 (1–3) |
Baseline anticoagulation | |||
 Yes | 153 (51.3) | 139 (47.6) | 292 (49.5) |
 Previous Use | 46 (15.4) | 47 (16.1) | 93 (15.8) |
 No | 96 (32.2) | 105 (36.0) | 201 (34.1) |
 Missing | 3 (1.0) | 1 (0.3) | 4 (0.7) |
Type of antithrombotic | |||
 Aspirin | 92 (30.9) | 102 (34.9) | 194 (32.9) |
 Clopidogrel | 12 (4.0) | 13 (4.5) | 25 (4.2) |
 Combined Antiplateleta | 12 (4.0) | 17 (5.8) | 29 (4.9) |
 Anticoagulant+Antiplateletb | 13 (4.4) | 17 (5.8) | 30 (5.1) |
 Warfarin | 125 (41.9) | 104 (35.6) | 229 (38.8) |
 Dabigatran | 14 (4.7) | 16 (5.5) | 30 (5.1) |
 Clexane | 1 (0.3) | 2 (0.7) | 3 (0.5) |
 None | 29 (9.7) | 21 (7.2) | 50 (8.5) |